Clinical Features and Survival Outcomes in Patients with Multiple Myeloma: Analysis of Web-Based Data from the Korean Myeloma Registry

Abstract

Aim: The Korean Multiple Myeloma Working Party performed a nationwide registration of multiple myeloma patients via a web-based data bank system. Methods: We retrospectively analyzed registered data from 3,209 patients since 1999. Results: The median overall survival (OS) was 50.13 months (95% confidence interval: 46.20–54.06 months). Patients ≤40 years demonstrated a longer OS than patients >65 years of age (median OS 71.13 vs. 36.73 months, p < 0.001). Patients who received novel agents at any time during their treatments showed a longer OS than patients who did not (median OS 42.23 vs. 55.50 months, p < 0.001). Response to treatment was associated with OS, with tandem autologous stem cell transplantation (SCT) producing longer OS than single autologous SCT. Conclusions: We demonstrated associations between survival outcomes and treatment modalities as well as baseline disease characteristics in a registry of multiple myeloma patients using a web-based data analysis.

Thalidomide, Cyclophosphamide and Dexamethasone Induction Therapy: Feasibility for Myeloma Patients Destined for Autologous Stem Cell Transplantation

“…Its incidence is also increasing in Asia, making myeloma the third-most common hematologic malignancy after lymphoma and myeloid leukemia in Korea [25]. With advances in treatment, including the development of novel agents and the accumulation of experience with these agents, outcomes for myeloma have improved [26]. Newer agents such as bortezomib and lenalidomide have diminished thalidomide's role in induction treatment, but, owing to the expense of the novel agents, it is still used in many countries.…”

Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party

“…Currently, more than 4,000 patients who were diagnosed after the year of 2,000 are registered from 41 institutes. We have documented the basic feature of this population [33].…”

Successful Treatment of Immunoglobulin D Myeloma by Bortezomib and Dexamethasone Therapy

“…On the other hand, Kim et al reported that the prognosis of IgD myeloma remains poor, and the median overall survival of 75 patients with IgD myeloma was 18.5 months, compared with 50.1 months for all myelomas in a Korean multicenter retrospective analysis (2). Thus, the IgD subtype might be an independent risk factor at the present time.…”

“…Few case series are available for IgD myeloma, but it is generally recognized as having aggressive clinical behavior, such as osteolytic lesions, renal impairment, hypercalcemia, anemia, extramedullary plasmacytoma, and amyloidosis (1)(2)(3)(4). Recently, myeloma survival has markedly improved by high-dose chemotherapy with autologous stem cell transplantation (SCT) (5), bortezomib (6), and immunomodulatory drugs, although reports concerning the treatments and responses of IgD myeloma are still limited (2)(3)(4). We report here a case of successful treatment of IgD myeloma with bortezomib and dexamethasone (BD) therapy.…”